` PRLD (Prelude Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

PRLD
vs
S&P 500

Over the past 12 months, PRLD has significantly outperformed S&P 500, delivering a return of +73% compared to the S&P 500's +14% growth.

Stocks Performance
PRLD vs S&P 500

Loading
PRLD
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PRLD vs S&P 500

Loading
PRLD
S&P 500
Difference
www.alphaspread.com

Performance By Year
PRLD vs S&P 500

Loading
PRLD
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Prelude Therapeutics Inc vs Peers

S&P 500
PRLD
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Prelude Therapeutics Inc
Glance View

Market Cap
134.5m USD
Industry
Biotechnology

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.

PRLD Intrinsic Value
12.59 USD
Undervaluation 83%
Intrinsic Value
Price
Back to Top